10x Genomics (TXG) – Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of 10x Genomics (NASDAQ: TXG) recently:

• 11/17/2025 – 10x Genomics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/15/2025 – 10x Genomics was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/11/2025 – 10x Genomics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – 10x Genomics had its price target raised by analysts at Piper Sandler from $15.00 to $19.00. They now have a “neutral” rating on the stock.
• 11/10/2025 – 10x Genomics was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 11/7/2025 – 10x Genomics had its price target raised by analysts at Canaccord Genuity Group Inc. from $16.00 to $19.00. They now have a “buy” rating on the stock.
• 11/7/2025 – 10x Genomics had its price target raised by analysts at JPMorgan Chase & Co. from $13.00 to $15.00. They now have a “neutral” rating on the stock.
• 11/7/2025 – 10x Genomics had its price target raised by analysts at UBS Group AG from $13.00 to $14.00. They now have a “neutral” rating on the stock.
• 11/7/2025 – 10x Genomics had its price target raised by analysts at Barclays PLC from $15.00 to $17.00. They now have an “overweight” rating on the stock.
• 10/14/2025 – 10x Genomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/9/2025 – 10x Genomics was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/3/2025 – 10x Genomics was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 9/27/2025 – 10x Genomics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity at 10x Genomics

In related news, CFO Adam Taich sold 22,315 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the sale, the chief financial officer owned 309,273 shares in the company, valued at $4,264,874.67. This represents a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the transaction, the insider owned 440,888 shares of the company’s stock, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 39,149 shares of company stock valued at $539,865 in the last quarter. Insiders own 9.39% of the company’s stock.

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.